Please assess the completion status of the following clinical trial:

Trial Title: Long Term Administration Study of OPC-12759 Ophthalmic Suspension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Out patient;~2. Ocular discomfort severity is moderate to severe;~3. Corneal-conjunctival damage is moderate to severe;~4. Unanesthetized Schirmer's test score of 5mm/5minutes or less,or tear breakup time is 5 seconds or less;~5. Best corrected visual acuity of 0.2 or better in both eyes.~Exclusion Criteria:~1. Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca;~2. Ocular hypertention patient or glaucoma patient with ophthalmic solution;~3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;~4. Anticipated use of contact lens during the study;~5. Patient with punctal plug;~6. Any history of ocular surgery within 12 months;~7. Female patients who are pregnant, possibly pregnant or breast feeding;~8. Known hypersensitivity to any component of the study drug or procedual medications;~9. Receipt of any investigational product within 4 months.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OPC-12759 Ophthalmic suspension (Type: EXPERIMENTAL): Instillation, 4times/day

Based on this trial design, predict the completion outcome and termination type (if applicable).